Efficacy of Quetiapine in Generalised Social Anxiety Disorder

Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00302770

Enrollment

Registered

2006-03-15

Start date

2006-06-30

Completion date

2006-12-31

Last updated

2011-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social Anxiety Disorder

Keywords

Patients with SAD

Brief summary

This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with the LSAS

Interventions

DRUGquetiapine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Written Confirmed Consent, * All patients meet the DSM IV criteria for generalized social anxiety disorder, * A score ≥ 60 on the LSAS, * male and female aged between 18 and 65 years

Exclusion criteria

* Presence of any primary axis I diagnosis other than social anxiety disorder according to DSM-IV, * alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months, * any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder, * patients at risk of suicide

Design outcomes

Primary

Measure	Time frame
Change on Lebowitz Social Anxiety Scale (LSAS) from baseline to endpoint	—

Secondary

Measure	Time frame
Number of responders, time to onset of response of sustained response to treatment	—

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026